Coherus BioSciences: A drugmaker with a 501% upside potential
Coherus BioSciences is a biopharmaceutical company that focuses on two areas: biosimilars and immuno-oncology. The company has three biosimilars on the market: Udenyca, a Neulasta biosimilar; Cimerli, a Lucentis biosimilar; and Yusimry, a Humira biosimilar. Moreover, the company recently won FDA approval for its immuno-oncology drug, Loqtorzi, as a treatment for advanced nasopharyngeal carcinoma. Coherus plans to launch Loqtorzi in the first quarter of 2024.
Despite its growing product portfolio, Coherus' stock has still plummeted by 74% this year. The main issue is the company's unfavorable cash situation. Coherus has less than a year of cash left at its current burn rate. Now, management has pledged to reduce expenses to move the company back to profitability. But investors appear to be waiting for hard evidence that this plan will bear fruit.
Beeindruckendes Handelsvolumen, allerdings bei einer Marktkapitalisierung von 240 Mio handelt es sich hier doch um ein sehr kleines Pharmaunternehmen. Ist hier nicht eher die Wahrscheinlichkeit, dass dieses Unternehmen aufgekauft wird?
Das würde für mich auch einen nachzhaltigen aufwärtstrend signalisieren und ggf. „Glücksritter“ rauskegeln. Mal schauen…so bleibt es zunächst äußerst spekulativ. Ich weiß, es gibt wohl einige Analysten, die hier bis 12 Dollar sehen…Analysten eben ;-) Gewinnmitnahmen würden mich allerdings heute leider auch nicht wundern.
December 28, 2023 Year in Review: Top Deals in 2023
Coherus Agrees to Acquire a Biosimilar EYLEA Candidate from Klinge Biopharma
In January, Coherus BioSciences, Inc. (“Coherus”) announced the execution of a binding term sheet with Klinge Biopharma GmbH (“Klinge Biopharma”) for the exclusive commercialization rights to FYB203, Formycon AG’s (“Formycon”) biosimilar candidate to EYLEA (aflibercept), in the United States. Under the binding term sheet, Coherus will make a total upfront payment to Klinge of approximately €30 million, comprised of cash and Coherus common stock, thirty days after the execution of the definitive agreements. Coherus will also make other regulatory and launch milestone payments and share profits approximately equally with Klinge in consideration for the commercialization rights to FYB203 in the United States. Formycon AG is entitled to participate in all Klinge income under the agreement with Coherus in the mid-single to low-double-digit-percentage range. Coherus intends to launch the product at EYLEA biosimilar market formation, currently expected to be in 2025, if approved.
Coherus BioSciences, Inc. Tue, January 2, 2024 at 2:29
Launch of LOQTORZI offers first and only FDA-approved treatment for NPC in all lines of therapy
Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients with disease progression on or after platinum containing chemotherapy, irrespective of PD-L1 status
LOQTORZI is now available for purchase through select specialty distributors
großer_prinz
: LOQTORZI is the first FDA-approved therapy for NPC
LOQTORZI is the first FDA-approved therapy for NPC and will represent a new standard of care for treating the disease when used in combination with cisplatin and gemcitabine in the first line setting or as monotherapy in the second line or greater setting.
Thread abonnieren
